Adjuvant or neoadjuvant chemotherapy for NSCLC.

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Research

Background:

• Surgical resection is standard for localized non-small cell lung cancer (NSCLC) in fit patients.
• Chemotherapy is indicated for stages II-III NSCLC, with debate on neoadjuvant vs. adjuvant timing.
• Adjuvant chemotherapy is guideline-recommended for early and locally advanced NSCLC (stages II-III).

Purpose of the Study:

• To evaluate the optimal timing of chemotherapy in non-small cell lung cancer (NSCLC).
• To compare neoadjuvant chemotherapy followed by surgery versus adjuvant chemotherapy post-surgery.
• To synthesize evidence regarding neoadjuvant versus adjuvant chemotherapy in NSCLC treatment.

Main Methods:

• Review of clinical practice guidelines, including European Society of Medical Oncology (ESMO) recommendations.
• Analysis of clinical trial data, such as the NATCH trial.
• Meta-analysis of studies comparing neoadjuvant and adjuvant chemotherapy strategies.

Main Results:

• Adjuvant chemotherapy is established in guidelines for NSCLC stages II-III and considered for stage IB (>4 cm tumors).
• Limited trials directly compare neoadjuvant therapy plus surgery with surgery alone.
• Existing trials and meta-analyses show no significant survival difference between neoadjuvant and adjuvant chemotherapy.

Conclusions:

• Postoperative (adjuvant) chemotherapy is the preferred timing for non-small cell lung cancer (NSCLC) due to strong evidence.
• While neoadjuvant and adjuvant approaches show similar survival outcomes, adjuvant therapy remains the standard.
• Further research may be ongoing, but current evidence supports the established adjuvant chemotherapy protocol.